Pancreatic Ductal Adenocarcinoma (PDAC)
Patient Condition
The 56-year-old patient developed upper abdominal pain and emaciation. CT showed a 4.2-cm mass in the pancreatic body, CA19 -9 1250 U/mL. Biopsy was confirmed as pancreatic ductal adenocarcinoma (PDAC), CT staging was locally advanced (T3N1M0), and the tumor surrounded the celiac trunk and superior mesenteric artery and was unresectable. At diagnosis, ECOG score was 2, weight loss was 8kg, and CA19 -9 was 1250 U/mL. Genetic testing: KRAS G12D mutation, no BRCA mutation.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| Evaluation and transformation treatment plan development | ||
| Transformation therapy (intensive chemotherapy + immunity) | ||
| Transformation surgery and reconstruction | ||
| Postoperative assistance and long-term follow-up |
Treatment Outcome
| before | Locally advanced pancreatic cancer, tumor 4.2 cm enclosing large vessels, CA19 -9 1250 U/mL, unresectable, ECOG 2, very poor prognosis |
|---|---|
| after | The R0 conversion operation was successful, and he survived disease-free 24 months after surgery. CA19 -9 was normal, nutritional status was good, and he returned to normal work. |
| highlight | Transformation therapy achieves tumor decline, from unresectable to R0 surgical resection +24 months of disease-free survival, bringing radical treatment opportunities for patients with locally advanced pancreatic cancer |